105,619 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 105,619 shares of the company's stock, valued at approximately $3,692,000. Raymond James Financial Inc. owned 0.07% of Ionis Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company's stock valued at $106,922,000 after purchasing an additional 183,814 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Ionis Pharmaceuticals by 2.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,481,440 shares of the company's stock valued at $51,791,000 after buying an additional 38,420 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Ionis Pharmaceuticals by 3.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company's stock valued at $53,376,000 after buying an additional 45,300 shares during the last quarter. Groupama Asset Managment increased its position in Ionis Pharmaceuticals by 4.1% in the 3rd quarter. Groupama Asset Managment now owns 916,060 shares of the company's stock worth $367,000 after buying an additional 36,084 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 13.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company's stock worth $26,070,000 after buying an additional 77,909 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company's stock.

Remove Ads

Ionis Pharmaceuticals Price Performance

Ionis Pharmaceuticals stock traded down $0.98 during trading hours on Monday, hitting $30.17. 2,042,899 shares of the stock were exchanged, compared to its average volume of 1,450,964. Ionis Pharmaceuticals, Inc. has a 12 month low of $29.61 and a 12 month high of $52.34. The business's 50-day moving average is $32.50 and its two-hundred day moving average is $35.63. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The stock has a market capitalization of $4.80 billion, a P/E ratio of -9.92 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million during the quarter, compared to analysts' expectations of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The business's revenue was down 30.2% on a year-over-year basis. During the same period last year, the firm posted $0.12 EPS. Equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IONS has been the topic of a number of research reports. StockNews.com raised shares of Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals in a report on Monday. They set a "neutral" rating and a $39.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. JPMorgan Chase & Co. lowered their price target on Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating on the stock in a research note on Monday, March 24th. Finally, BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday, February 20th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $58.37.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 8,870 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.81, for a total value of $291,024.70. Following the transaction, the chief financial officer now directly owns 107,885 shares in the company, valued at approximately $3,539,706.85. This trade represents a 7.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brett P. Monia sold 38,843 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total value of $1,229,380.95. Following the completion of the sale, the chief executive officer now directly owns 180,683 shares of the company's stock, valued at $5,718,616.95. This trade represents a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 111,956 shares of company stock worth $3,608,439. 2.71% of the stock is currently owned by corporate insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.